Coverage from AAPS PharmSci 360 and CPHI Milan featured discussion about impurities, devices, and supply resilience. This week also included topics such as AI accountability, oral peptides, and new licensing deals.
News|Articles|December 2, 2004
- Pharmaceutical Technology-12-02-2004
- Volume 28
- Issue 11
In Between the Light and the Dark: Developments in Photosensitive Pharmaceuticals
Researchers are improving photodynamic therapies with new photosensitizers and light sources for deeper tissue penetration, more site-specific treatments, and reduced side effects.
Advertisement
Articles in this issue
almost 22 years ago
In the Spotlight-December 2004almost 22 years ago
Safety Problems Roil Pharma and FDAalmost 22 years ago
December 2004almost 22 years ago
Robust CRO Market Is Driving New Merger and Acquisition Activityalmost 22 years ago
The Seventh Annual International Employment Surveyalmost 22 years ago
Pharmaco-FakeryAdvertisement
Related to this article
The FDA grants accelerated approval to subcutaneous amivantamab for head and neck cancer, extending the IV-to-subcutaneous shift in biologics formulation.
Almac Clinical Services’ clinical supply strategy won the 2026 CPHI Award for Supply Chain Excellence. Nishma Patel, supply chain solutions manager, explains the benefits and challenges of the company’s just-in-time manufacturing solution.
Vivek Gupta of Duquesne University explains at AAPS PharmSci 360 why device decisions can't wait and why excipient makers must test beyond drug molecules.
This week addressed AI accountability, CPHI award winners, NFC anticounterfeiting, first-in-class FDA approvals, and a shelved FDA voucher pilot lead this week’s roundup.
Cole and Jaenisch explain why defending against AI poisoning in pharma manufacturing calls for a data steward role, immutable instruction ledgers, and automation.
Terry Katz, CEO and co-founder of ForgeStop Technology Corporation, explains how the company’s product is worth the investment by protecting products and patients.
The FDA has shelved its National Priority Voucher pilot, leaving sponsors that built CMC and launch-readiness plans around 1- to 2-month reviews facing uncertain timelines.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Signs Point to FDA Shelving Priority Voucher Pilot, Stalling Fast-Track Drug Reviews
2
France Remains One of Europe’s Leading Biotech Funding Hubs
3
PharmTech AI Pulse Check: Who's Accountable When a Vendor's AI Model Changes?
4
The Impact of Excipients on Continuous Manufacturing and the Risk of Nitrites
5